Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.78M, -77.2% YoY · Filed Aug 17, 2026
DataMeds AI, Inc. (MEDS) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.8 million and a net loss of $18.4 million. As of Jun 30, 2026 it held $2.5 million in cash and investments and $32.7 million in total debt.
Revenue
$1.78M
-77.2% vs year-ago quarter
Net income
$-18.36M
-175.2% vs year-ago quarter
Operating cash flow
$-2.89M
-39.2% vs year-ago quarter
Free cash flow
—
EPS
$-7.13
-32.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.06M
-96.4% vs year-ago quarter
Net cash
$-30.20M
Q2 FY2026
Operating margin
-875.7%
TTM
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- MEDS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2030763
- Former names
- Wellgistics Health, Inc. (until Jul 21, 2026); Danam Health, Inc (until Sep 27, 2024)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- Cellyan Biotechnology Co., Ltd HKPD
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.8M | $1.6M | $1.7M | $3.0M | $7.8M |
| Operating income | -$7.3M | -$6.0M | -$25.4M | -$31.5M | -$5.5M |
| Net income | -$18.4M | -$7.7M | -$27.9M | -$34.3M | -$6.7M |
| Diluted EPS | -$7.13 | -$0.07 | -$0.29 | -$0.46 | -$5.40 |
| Operating cash flow | -$2.9M | -$3.4M | -$6.3M | -$1.1M | -$2.1M |
| Total assets | $32.8M | $30.1M | $30.5M | $52.8M | $54.2M |
| Total liabilities | $52.3M | $45.2M | $42.9M | $46.0M | $53.3M |
| Stockholders' equity | -$19.5M | -$15.1M | -$12.4M | $6.8M | $905,255 |
| Cash and investments | $2.5M | $51,730 | $42,571 | $4.2M | $419,942 |
| Total debt | $32.7M | $28.8M | $24.7M | $26.1M | $24.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Agreement ended, Regulation FD disclosure
|
Nov 5, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 26, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement, Listing notice, Unregistered share sale
|
Oct 16, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 11, 2026 |
All 176 DataMeds AI, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.